Biotechnology company InduPro Inc announced on Wednesday that it has entered into a strategic equity investment and research collaboration with French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY).

The agreement includes a right of first negotiation for Sanofi on InduPro's bispecific PD-1 agonist programme, currently in preclinical development for the treatment of autoimmune and inflammatory disorders.

Sanofi will fund preclinical and IND-enabling research activities and make an undisclosed equity investment in InduPro.

InduPro leverages high-resolution proximity labelling technology to map membrane protein neighbourhoods, identifying novel co-target pairs for precise therapeutic intervention. The company's approach aims to create first-in-class and best-in-class therapeutic candidates by modulating cellular signalling pathways across multiple disease contexts.